SINGAPORE-Thursday 23 April 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Mundipharma today announced that it will embark on an ambitious series of studies both in vitro and in vivo to evaluate the effectiveness of its BETADINE®
antiseptic products against the novel coronavirus (SARS-CoV-2) which
causes COVID-19 disease. Testing will be initiated in collaboration with
BLS3 laboratories and experts in Asia, Europe and US.
The BETADINE®
antiseptic range, which is currently in high demand around the world,
contains Povidone-iodine (PVP-I), which is highly effective against a
wide range of microorganisms, including bacteria, viruses and fungi;
which is why you will typically see these products in most hospitals.
Past studies indicate that BETADINE®
antiseptic range of products are highly effective against a wide range
of viruses including coronaviruses such as MERS-CoV and SARS-CoV which
have caused major outbreaks such as Middle East Respiratory Syndrome
(MERS) and Severe Acute Respiratory Syndrome (SARS). PVP-I has also
demonstrated broad virucidal efficacy against Ebola virus, Norovirus and
Influenza viruses in several in-vitro studies.
“A range of studies have indicated that BETADINE®
antiseptic products were effective against the SARS and MERS
coronaviruses and we are aware of recent publications and medical
protocols encouraging the use of PVP-I solutions, so it makes sense that
we initiate studies in collaboration with experts for both invitro and
clinical studies,” said Mundipharma CEO, Raman Singh.
“My hope is that BETADINE®
antiseptic products can play a long-term role in keeping the curve
flat, once we return to a more normal business and community life. As a
business, we have been donating supplies of our BETADINE®
products to hospitals in the region to help healthcare professionals and
all those on the front line working tirelessly so that we can be safe
and resume our normal daily lives as soon as possible,” added Singh.
The BETADINE®
range of products containing Povidone-iodine or PVP-I has been trusted
by hospitals around the world for over 60 years to prevent and treat
infections, including antibiotic-resistant strains that cause
infections. PVP-I works by damaging microbial cell walls and structures
and disrupting metabolic pathways needed for microbial replication and
microbial viability. In layman’s terms, it effectively prevents
bacteria, viruses and fungi from taking hold.
“While we wait for the results of the tests on the effectiveness of our BETADINE®
antiseptic products against SARS-COV-2, it’s important to note that a
definitive confirmation of its efficacy against the virus causing
COVID-19 can only be provided once testing has been completed,” added
Singh.
“Nevertheless,
we are hopeful that through this research collaboration program we can
contribute to overcoming this global public health crisis.”
About BETADINE®
The BETADINE®
range of products have been trusted by hospitals and consumers around
the world for over 60 years to prevent and treat infections. Over the
last few years, Mundipharma has expanded the BETADINE® range
of products to include povidone-iodine and non-povidone iodine ranges
for the prevention, treatment and maintenance of a range of conditions
from upper respiratory tract infections, wound infections, feminine
hygiene and infections and outbreaks to personal and hand hygiene.
In-vitro and clinical studies have demonstrated that BETADINE® Povidone-Iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.
®: BETADINE is a registered trademark of Mundipharma
About Mundipharma
Mundipharma’s
independent associated companies are privately owned entities covering
the world’s pharmaceutical markets. Mundipharma is a prime example of a
company that consistently delivers high quality products while standing
by the values that represent the company. Our mission is to alleviate
the suffering of patients with cancer and non-cancer pain and to
substantially improve their quality of life. Mundipharma is dedicated to
bringing to patients with severe and debilitating diseases the benefit
of novel treatment options in fields such as pain, oncology, oncology
supportive care, ophthalmology, respiratory disease and consumer
healthcare.
For more information please visit: www.mundipharma.com.sg.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005435/en/
Contacts
Stephenie Vasko
Chief Communications Officer & Head, Digital Strategy
+65-6303-9732 | media@mundipharma.com.sg
No comments:
Post a Comment